Schering to collaborate with Combinature on combinatorial biosynthesis
Berlin, December 11, 2003 - Schering AG, Germany (FSE: SCH, NYSE: SHR) and
Combinature Biopharm AG, Germany, have signed a research agreement to apply
Combinature's proprietary combinatorial biosynthesis technology to generate
derivatives of one of Schering's lead compounds in the area of dermatology.
Under the terms of agreement, Combinature will receive R&D payments and
milestone payments. Schering will receive exclusive and worldwide rights
to develop and commercialize generated products in the area of dermatology.
Financial details were not disclosed.
"We view combinatorial biosynthesis as a novel tool to increase chemical
diversity and to modify even highly complex compounds," said Xxxx. Xxxxxx
Xxxxxxxxxx, Head of Schering Research Center Europe. "Combinature's
innovative approach to combine natural product research with genomic and
biocatalysis tools will contribute to Schering's development pipeline. We
look forward to working together with Combinature on this project with this
unique technology."
"We are delighted to work together with Xxxxxxxx on this project and about
their decision to take a close look at the advantages of our unique
approach in combinatorial biosynthesis," said Xx. Xxxx Xxxxx, Chief
Executive Officer of Combinature Biopharm AG.
About Combinature Biopharm AG
Combinature Biopharm AG is a drug discovery company which applies a unique
combinatorial biosynthesis technology. The Combinature aims to become a
leading provider of natural compound based pre-clinical and clinical
development candidates for the drug development market. Combinature is
financed by the 3i group plc., London, one of Europe's leading venture
capital companies, as its lead investor.
Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Gynecology&Andrology,
Diagnostics&Radiopharmaceuticals, Dermatology as well as Specialized
Therapeutics for disabling diseases in the fields of the central nervous
system, oncology and cardiovascular system. As a global player with
innovative products Schering AG aims for leading positions in specialized
markets worldwide. With in-house R&D and supported by an excellent global
network of external partners, Schering AG is securing a promising product
pipeline. Using new ideas, Schering AG aims to make a recognized
contribution to medical progress and strives to improve the quality of
life: making medicine work
This press release has been published by Corporate Communication of
Schering AG, Berlin, Germany.
Your contacts at Corporate Communication:
Business: Xx. Xxxxxxxxx xxx Xxxx, T: x00-00-000 152 96,
xxxxxxxxx.xxxxxxx@xxxxxxxx.xx
Xxxxxxxx Relations: Xxxxx Xxxx, T: x00-00-000 128 38,
xxxxx.xxxx@xxxxxxxx.xx
Find additional information at: xxx.xxxxxxxx.xx/xxx
